GLP-1 Monitoring Study

On Semaglutide or Tirzepatide?
Track Your Age Reversal

Early research suggests GLP-1 medications may reverse biological aging by 3-5 years. Join our study to track your epigenetic age as you lose weight.

Track Age Reversal
All GLP-1s Welcome
Quarterly Testing
The GLP-1 Longevity Connection
What emerging research shows
10+ years
Obesity accelerates biological aging by up to a decade
20%
Cardiovascular event reduction in semaglutide trials
Promising
GLP-1s may work through multiple aging pathways

GLP-1 epigenetic research is emerging - be part of the discovery

Beyond Weight Loss: The Longevity Question

GLP-1 medications like Ozempic, Wegovy, and Mounjaro are revolutionizing weight loss - but do they actually reverse biological aging?

Inflammation Reduction

Weight loss dramatically reduces chronic inflammation - a key driver of accelerated aging measured by GrimAge.

Metabolic Reset

GLP-1s improve insulin sensitivity, glucose control, and lipid profiles - all factors that influence epigenetic aging.

Cardiovascular Benefits

SELECT trial showed 20% CV event reduction - but is this just weight loss or something more? GrimAge can help answer this.

Frontier Research

Why Track Biological Age on GLP-1s?

You're investing in your health with GLP-1 therapy. Now quantify the return on that investment with rigorous biological age tracking.

Answer the Big Question

Does weight loss from GLP-1s actually reverse biological aging, or just improve symptoms?

Track Progress Beyond the Scale

Weight fluctuates, but biological age shows the deeper metabolic transformation

Compare GLP-1s

Help determine if semaglutide, tirzepatide, or others have different aging effects

Contribute to Science

Help generate the first large-scale data on GLP-1s and epigenetic aging

Track Your Transformation

Quarterly testing throughout your GLP-1 journey

0

Baseline

GrimAge test before or early in GLP-1 treatment

3

3 Months

First follow-up during rapid weight loss phase

6

6 Months

Mid-study assessment as metabolic changes stabilize

12

12 Months

Final assessment - quantify your biological age change

Pioneering Research Opportunity

Quantify Your GLP-1 Journey

You're already on the cutting edge with GLP-1 therapy. Now be on the cutting edge of understanding what it does to your biological age.

Study Eligibility

  • Currently on or starting semaglutide, tirzepatide, or other GLP-1
  • BMI 27+ (or 25+ with metabolic condition)
  • Willing to complete 4 blood draws over 12 months
  • Planning to continue GLP-1 therapy for at least 6 months
Check Eligibility & Enroll

Early enrollees receive discounted testing rates

Frequently Asked Questions

Will GLP-1s definitely reduce my biological age?

We don't know yet - that's why this study is important! Weight loss generally reduces biological age, and GLP-1s have effects beyond weight loss. This study will help determine if GLP-1s produce epigenetic age reversal.

Which GLP-1 medications are included?

All GLP-1 receptor agonists are welcome: semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), and others. We'll analyze results by medication type.

Can I join if I've already been on GLP-1 for a while?

Yes, though ideally we prefer participants early in their GLP-1 journey to capture baseline and changes. If you've been on GLP-1s for over 6 months, we may place you in a maintenance tracking cohort instead.

Do I need to share my results publicly?

No. Your individual results are private. We use anonymized, aggregate data for research publications. You own your data and can choose whether to share it.

What if I stop taking my GLP-1 during the study?

That's actually valuable data! We want to understand how biological age changes both on and off GLP-1 therapy. Please continue with scheduled tests even if you discontinue medication.